Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL trial: Obinutuzumab + Pixantrone in relapsed aggressive B-cell lymphoma
2014-004780-21Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and pixantrone in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more, sponsored by University Medical Center Mainz. Primary endpoint: Overall response rate at cycle 6 or individual treatment end. Started Apr 2015; status: completed.
02
Drugs
obinutuzumabpixantrone
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2014-004780-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004780-21.